Chronic Obstructive Pulmonary Disease (COPD)
COPD is characterised by persistent respiratory symptoms and limitation in the airflow, which is due to airway abnormalities, alveolar abnormalities or both. This is usually caused by significant exposure to noxious particles, gases or air pollutants in the home and workplace, genetic factors, and respiratory infections can also be involved.
Symptoms of COPD include dyspnoea (shortness of breath or breathlessness), frequent coughing or wheezing and excess phlegm, mucus or sputum production. Patients with severe COPD may develop a number of extra pulmonary symptoms, such as fatigue, anorexia and weight loss which correlate with disease exacerbations due to bacterial and viral infections.
Whereas smoking cessation and increased physical activity can be used to treat the impact of COPD, bronchodilators and anti-inflammatory drugs therapy (whether used in combination or alone) are the main therapies available. Pulmonary rehabilitation and supplemental oxygen can also be beneficial.
To find out more about COPD visit our dedicated Learning Zone, which contains further information on treatment, medication and guidelines for this condition.
Featured Learning Zones
The Respiratory Care Learning Zone contains essential information on Inhaled Therapies in Asthma and COPD and its Management. The Learning Zone also has an Educational Resources section which features slide kits, congress news and webinars and videos relevant to asthma and COPD.
Freshly updated for 2017, the latest edition of the Global Strategy document is the premiere evidence-based reference tool for the implementation of effective disease management plans, and represents the current best practices...
Related news and insights
Novartis and Molecular Partners AG announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin program, consisting of two therapeutic candidates, MP 0420 and MP 0423.
AstraZeneca’s Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide), has been recommended for marketing authorisation in the European Union (EU) for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA), or a combination of a LABA and a long-acting muscarinic antagonist.